{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"15"}],"units":"Participants"}],"description":"MRD-free is defined as participants with no hairy cell leukemia (HCL) in the blood and bone marrow aspirate flow determined by immunohistochemistry (IHC) and flow cytometry of blood and bone marrow aspirate.","groups":[{"description":"Participants with Relapsed/Refractory Hairy Cell Leukemia (HCL) or Hairy Cell Leukemia (HCLv)\n\nArm 1 Moxetumomab Pasudotox-tdfk + Rituximab\n\nDose escalation treatment with moxetumomab -pasudotox-tdfk and rituximab Moxetumomab pasudotox-tdfk is administered at 30-40 ug/Kg intravenous (iv) over 30 min given on days 1, 3, 5 of each cycle.\n\nRituximab will be administered at 375mg/m\\^2 iv, 50-400 mg/hour (hr). On cycle 1, Rituximab is given on day -2, on subsequent cycles, Rituximab is given on day 1.","id":"OG000","title":"Moxetumomab - Dose Escalation 30 mcg/kg"},{"description":"Dose expansion; treatment with moxetumomab -pasudotox-tdfk and Ruxience\n\nArm 1 and Arm 2 Moxetumomab Pasudotox-tdfk + Ruxience\n\nMoxetumomab pasudotox-tdfk is administered at 30-40 ug/Kg intravenous (iv) over 30 min given on days 1, 3, 5 of each cycle.\n\nRuxience will be administered at 375mg/m\\^2 iv, 50-400 mg/hour (hr). On cycle 1, Ruxience is given on day -2, on subsequent cycles, Ruxience is given on day 1 (Delta)","id":"OG001","title":"Moxetumomab - Dose Expansion 40 mcg/kg"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"28-42 days after day 1 of the last treatment.","title":"Number of Participants Who Are Minimal Residual Disease (MRD)-Free","type":"SECONDARY","unitOfMeasure":"Participants"}